Adamis Pharmaceuticals Corporation
ADMP
$0.2113
-$0.0087-3.96%
Weiss Ratings | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | D | |||
Rating Factors | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | -- | |||
Solvency Index | Good | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.46 | |||
Price History | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 7.86% | |||
30-Day Total Return | 32.15% | |||
60-Day Total Return | 48.59% | |||
90-Day Total Return | -6.59% | |||
Year to Date Total Return | 27.98% | |||
1-Year Total Return | -67.24% | |||
2-Year Total Return | -85.43% | |||
3-Year Total Return | -69.51% | |||
5-Year Total Return | -93.96% | |||
52-Week High % Change | -70.05% | |||
52-Week Low % Change | 83.33% | |||
Price | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $0.73 | |||
52-Week Low Price | $0.12 | |||
52-Week Low Price (Date) | Oct 11, 2022 | |||
52-Week High Price (Date) | Mar 01, 2022 | |||
Valuation | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | $33.00M | |||
Enterprise Value | 31.57M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.22 | |||
Earnings Per Share Growth | -52.12% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 21.57 | |||
Price/Book (Q) | 11.58 | |||
Enterprise Value/Revenue (TTM) | 20.49 | |||
Price | $0.21 | |||
Enterprise Value/EBITDA (TTM) | -1.10 | |||
Enterprise Value/EBIT | -1.05 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 149.983M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 858 997 2400 | |||
Address | 11682 El Camino Real San Diego, CA 92130 | |||
Website | www.adamispharmaceuticals.com | |||
Country | United States | |||
Year Founded | 2006 | |||
Profitability | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -1,957.92% | |||
Profit Margin | -2,072.23% | |||
Management Effectiveness | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -65.90% | |||
Return on Equity | -- | |||
Income Statement | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | $1.54M | |||
Total Revenue (TTM) | $1.54M | |||
Revenue Per Share | $0.01 | |||
Gross Profit (TTM) | -$3.92M | |||
EBITDA (TTM) | -$28.69M | |||
EBIT (TTM) | -$30.16M | |||
Net Income (TTM) | -$31.92M | |||
Net Income Avl. to Common (TTM) | -$31.92M | |||
Total Revenue Growth (Q YOY) | 98.12% | |||
Earnings Growth (Q YOY) | 17.36% | |||
EPS Diluted (TTM) | -$0.22 | |||
EPS Diluted Growth (Q YOY) | 64.70% | |||
Balance Sheet | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | $2.42M | |||
Cash Per Share (Q) | $0.02 | |||
Total Current Assets (Q) | $10.09M | |||
Total Preferred Equity (Q) | $0.16 | |||
Total Equity (Q) | $3.00M | |||
Current Ratio (Q) | 1.137 | |||
Book Value Per Share (Q) | $0.02 | |||
Total Assets (Q) | $12.14M | |||
Total Current Liabilities (Q) | $8.87M | |||
Total Debt (Q) | $840.10K | |||
Total Liabilities (Q) | $9.13M | |||
Total Common Equity (Q) | $2.85M | |||
Cash Flow | ADMP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | $4.49M | |||
Cash from Financing (TTM) | $242.20K | |||
Net Change in Cash (TTM) | -$26.31M | |||
Levered Free Cash Flow (TTM) | -$13.28M | |||
Cash from Operations (TTM) | -$31.05M | |||